Integration of high-risk human papillomavirus DNA is linked to the down- regulation of class I human leukocyte antigens by steroid hormones in cervical tumor cells

Cancer Research

Volumn 57, Issue 5, 1997, Pages 937-942

  Bartholomew, Jennifer S ^a   Glenville, Suzanne ^a   Sarkar, Somdatta ^b   Burt, Debbie J ^a   Stanley, Margaret A ^b   Ruiz Cabello, Francisco ^c   Chengang, Jin ^a   Garrido, Federico ^c   Stern, Peter L ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; HYDROCORTISONE; PROGESTERONE; STEROID HORMONE; VIRUS DNA;

ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG CONTRAINDICATION; HORMONE ACTION; HUMAN; HUMAN CELL; PRECANCER; PRIORITY JOURNAL; UTERINE CERVIX CANCER; WART VIRUS;

CARCINOMA; DNA, VIRAL; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE EXPRESSION REGULATION, VIRAL; HISTOCOMPATIBILITY ANTIGENS CLASS I; HORMONE ANTAGONISTS; HUMANS; HYDROCORTISONE; MIFEPRISTONE; PAPILLOMAVIRIDAE; PROGESTERONE; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS; VIRUS INTEGRATION;

EID: 0031036696     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. zur Hausen, H. Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers. Cancer Res., 41: 4677-4681. 1989.
2. Lorincz, A. T., Reid. R., Jenson, A. B., Greenberg, M. D., Lancaster, W., and Kurmun. R. J. Human papillomavirus infection of the cervix, Relative risk associations of 15 common anogenital types. Obstet. Gynecol., 79: 328-327. 1992.
3. zur Hausen, H., and de Villiers, E. M. Human papillomaviruses. Ann. Rev. Microbiol., 48: 427-447, 1994.
4. Lehn, H., Villa. L. L., Marziona. F., Hilgarth, M., Hillemans, H. G., and Sauer, G. Physical state and biological activity of human papillomavirus genomes in precancerous lesions of the female genital tract. J. Gen. Virol., 69: 187-196, 1988.
5. Durst, A, P., Kleinheinz, A., Hotz, M., and Gissmann, L. The physical state of human papillomavirus type 16 DNA in benign and malignant genital tumours. J. Gen Virol., 66: 1512-1522, 1985.
6. Cullen, A. P., Reid, R., Campion, M., and Lorincz, A. T. Analysis of the physical states of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasia. J. Virol., 65: 606-612, 1991.
7. Choo, K, B., Pass, C. C., and Han, S. H. Integration of human papillomavirus type 16 into cellular DNA of cervical carcinoma: preferential deletion of the E2 gene and invariable retention of the long control region and the E6/E7 ORFs. Virol. 161: 259-261, 1987.
8. Choo, K., Lee, H. H., Pan, C. C., Wu, S. M., Liew, L. N., Cheung,W. F., and Han, S. H. Sequence duplication and internal deletion in the integrated human pupillomavirus type 16 genome cloned from a cervical carcinoma. J. Virol., 62: 1659-1666, 1988.
9. Berumen, J., Casas, L., Seguru, E., Amezana, J. L., and Garcia-Carranca, A. Genome amplification of human papillomavirus types 16 and 18 in cervical carcinomas is related to the retention of E1/E2 genes. Int. J. Cancer., 56: 640-645, 1994.
10. Dong, G., Broker, T. R., and Chow, L. T. Human papillomavirus type 11 E2 proteins repress the homologous E6 promoter by interfacing with the binding of host transcription factors to adjacent elements. J. Virol., 68: 1115-1127. 1994.
11. Ham, J., Dostatni, N., Gauthier, J., and Yaniv, M. The papillomavirus E2 protein: a factor with many talents. Trends Biochem. Sci., 16: 440-444. 1991.
12. Romanczuk, H., Thiery, F., and Howley, P. M. Mutational analysis of cis elements involved E2 modulation of human papillomavirus type 16 p97 and p105 promoters. J. Virol., 64: 2849-2859. 1991.
13. Sang, B. C., and Barbosa, M. S. Increased E6/E7 transcription in HPV 18 immortalized human keratinocytes results from inactivation of E2 and additional cellular events. Virology. 189: 448-455, 1992.
14. Brisson, J., Morin. C., Fortier, M., Roy, M., Bouchard, C., Leclerc. J., Christen, A., Guimom, C., Penault, F., and Meisels, A. Risk factors for cervical intraepithelial neoplasia, differences between high and low grade lesions, Am. J. Epidemiol., 140: 700-710, 1994.
15. Laga, M., Icenogle, J. P. Marsella, R., Manoka, A. T., Nzila, N., Ryder, A. W., Vermund, S. H., Heyward, W. L., Nelson, A., and Reeves, W. C. Genital papillomavirus infection and cervical dysplasia-opportunistic complications of HIV infection. Int, J. Cancer., 50: 45-48, 1992.
16. Schneider, A., and Koutsky, L. A. Natural history and epidemiological features of genital HPV infection. IARC Sci, Publ., 119: 25-52, 1992.
17. Pater, M. M., Hughes, G. A., Hyslop, D. E., Nakshatri, H., and Pater. A. Glucocorticoid-dependent oncogenic transformation by type 16 but not type 11 human papillomavirus DNA. Nature (Lond.), 335: 832-835, 1988.
18. Crook, T., Storey. A., Almond, N., Osborn, K., and Crawford, L. Human papillomavirus type 16 co-operates with activated ras and fos oncogenes in the hormone dependent transformation of primary mouse cells. Proc. Natl. Acad Sci, USA., 85: 8820-8824, 1988.
19. Chan. W, K., Klock, G., and Bernhardt, H. U. Progesterone and glucocorticoid response elements occur in the long control regions of several human papillomavirus involved in anogenital neoplasia. J, Virol., 63: 3261-3269, 1989.
20. Mittal, R., Kouichiro, T., Pater, A., and Pater, M. M. Human papillomavirus type 16 expression in cervical keratinocytes: role of progesterone and glucocorticoid hormones. Obstet. Gynecol., 81: 5-12, 1993.
21. Hildesheim, A., Reeves, W. C., Brinton. L., Lavery. C., Brenes, M., De La Guardia, M., Godoy, J., and Rawls, W. E. Association of oral contraceptive use and human papillomaviruses in invasive cancers. Int. J. Cancer., 45: 860-864, 1990.
22. Munoz, N., Bosch, F. X., deSanjose, S., and Shah, K. V. The role of HPV in the etiology of cervical cancer. Mutat. Res., 305: 293-301, 1994.
23. Brinton, L. A., Huggins, G. R. Lehman, H. F., Mallin, K., Savitz, D. A., Trapido, D, A., Rosenthal, J., and Hoover, R. Long-term use of oral contraceptives and risk of invasive cervical cancer. Int. J. Cancer., 38: 339-344. 1986.
24. World Health Organisation Collaborative Study of Neoplasia and Steroid Contraceptives. Invasive cervical cancer and combined orul contraceptives. Br. Med. J., 290: 961-965, 1985.
25. Berul, V., Hannaford, P., and Kay, C. Oral contraceptive use and malignancies of the , genital tract. Lancet, 2(8624): 1331-1335, 1988.
26. Stern, E., Forsythe, A. B., Youkeles, L., and Coffedt, C. F. Steroid contraceptive use and cervical dysplasia. Increased risk of progression. Science (Washington DC), 196: 1460-1462, 1977.
27. Brinton, L. A. Oral contraceptives and cervical neoplasia. Contraception., 43: 581-587, 1991.
28. Garrido, F., Cabrera, T., Concha, A., Glew, S. S., Ruiz-Cabello, F., and Stern, P. L. Natural history of HLA expression during tumour development. Iinmunol. Today, 14: 491-499, 1993.
29. Keating, P. J., Cromme, F. V., Duggan-Keen, M., Snijders, P. J. F., Waalboomers, J. M., Hunter, R. D., Dyer, P. A., and Stern, P. L. Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br. J. Cancer, 72: 405-411, 1995.
30. Rheinwald, J. G., and Green, H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell. 6: 331-344, 1975.
31. Stanley, M. A., Browne, H. M., Appleby, M., and Minson, A. C, Properties of a non-tumorigcnic human cervical keratinocyte cell line. Int. J. Cancer, 43: 672-676, 1989.
32. Bernhard, H., Karbach, J., Wolfel, T., Busch, P., Storkel, S., Stockle, M., Wolfel, C., Seliger, B., Huber, C., Meyer zum Buschenfelde, K. H., and Knuth, A. Cellular immune response to human renal-cell carcinomas: definition of a common antigen recognized by HLA-A2 restricted cytotoxic T-lymphocyte clones. Int. J. Cancer, 59: 837-842, 1994.
33. Fujinaga, Y., Shimada, M., Okazawa, K., Fukushima, M., Kato, I., and Fujinaga, K. Simultaneous detection and typing of genital human papillomavirus DNA using the polymerase chain reaction. J. Gen. Virol., 72: 1039-1044, 1991.
34. Dignam, J. D. Lebovitz, R. M., and Roeder, R. G. Accurate transeriptional initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res., 11: 1475-1489, 1983.
35. Rodriguez, F., Peran, F., Garrido, F., and Ruiz-Cabello, F. Upmodulation by estrogen of HLA class I expression in breast tumour cell lines. Immunogenetics. 39: 161-167, 1994.
36. Hole, N., Barton-Hanson, N., Berwick, S., and Stern, P. Human trophoblast glycoproteins defined by monoclonal antibody 1D2. Exp. Cell. Biol., 56: 39-48, 1988.
37. Beato, M. Gene regulation by steroid hormones. Cell. 56: 335-344. 1989.
38. von Knebel Doeberitz, M., Koch, S., Drzonek, H., and zur Hausen, H, Glucocorticoid , hormones reduce the expression of major histocomputibility class I antigens on human epithelial cells. Eur. J. Immunol., 20: 35-40, 1990.
39. Durst, M., Croce, C. M., Gissmann, L., Schwarz, E., and Huebner. K. Papillomavirus sequences integrate near cellular oncogenes in some cervical carcinomas. Proc. Natl. Acad. Sci. USA, 84: 1070-1074, 1987.
40. Popescu, N. C., Amsbaugh, S. C., and DiPaolo, J. A. Human papillomavirus type 18 DNA is integrated at a single chromosome site in SW756. J. Virol., 61: 1682-1685. 1987.
41. Jeon, S., and Lambert, P. F. Integration of human papillomavirus type 16 into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proc. Natl. Acad. Sci. USA, 92: 1654-1658, 1995.
42. Von Knebel Doeberitz, M., Bauknecht, T., Bartsch, D., and zur Hausen, H. Influence of chromosomal integration on glucocorticoid-regulated transcription of growth-stimulating papillomavirus genes E6 and E7 in cervical carcinoma lines. Proc. Natl, Acad. Sci. USA, 88: 1411-1415, 1991.
43. Jeon, S., Allen-Hoffmann, B. L., and Lambert, P. F. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J. Virol., 69: 2989-2987, 1995.
44. Plaksin, D., Bueuerle, P. A., and Eisenbach, L. KBF1 p50 NF-kB homodimer acts as a repressor of H-2Kb gene expression in metastatic tumour cells. J. Exp. Med., 177: 1651-1662, 1993.
45. Abril, E., Mendez, R. E., Garcia, A., Senrano, A., Cabrera, T., Garrido, F., and Ruiz-Cabello, F. Characterization of a gastric tumor cell line defective in MHC class I inducibility by both α and γ Interferon. Tissue Antigens, 47: 391-398. 1996.
46. Levitsky, V., Zhang, Q., Levitskayu, J., and Masucci. M. The life span of MHC-peptide complexes influences the efficiency of presentation und immunogenicity of two class I restricted cytotoxic T lymphocyte epitopes in the Epstein Barr nuclear antigen 4. J. Exp. Med., 183: 915-926, 1996.
47. al-Saleh, W., Delvenne, P., Arrese, J. E., Nikkels, A. F., Pierard, G. E., and Boniver, J. Inverse modulation of intraepithelial Langerhans cells and stromal macrophage/ dendrocyte populations in human papillomavirus-associatcd squamous intraepithelial lesions of the cervix. Virchows Archiv., 427: 41-48, 1995.
48. Zondervan, K. T., Carpenter, L. M., Painter, R., and Vessey, M. P. Oral contraceptives and cervical cancer: further findings from the Oxford Family Planning Association contraceptive study. Br. J. Cancer., 73: 1291-1297, 1996.